The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients.
Pancreas cancer
neoadjuvant chemoradiation
pCR
pathological response
survival
Journal
Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
07
2019
accepted:
04
03
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
17
7
2020
Statut:
epublish
Résumé
We aimed to study the impact of neoadjuvant chemotherapy to surgery (NCT-S) interval and neoadjuvant radiotherapy (NRT) on pathological complete response (pCR) and overall survival (OS) in pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]). National Cancer Data Base (NCDB)-pancreatectomy patients who underwent NCT/NRT were included. The NCT-S interval was divided into time quintiles in weeks: 8 to 11, 12 to 14, 15 to 19, 20 to 29, and >29 weeks. A total of 2093 patients with NCT were included with median follow-up of 74 months and 71% NRT. The pCR rate was 2.1% with higher median OS compared with non-pCR (41 vs 19 months, Longer NCT-S interval and pCR were independent predictors of improved OS in patients with PDAC. The NRT predicted increased pCR but not OS.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to study the impact of neoadjuvant chemotherapy to surgery (NCT-S) interval and neoadjuvant radiotherapy (NRT) on pathological complete response (pCR) and overall survival (OS) in pancreatic cancer (pancreatic ductal adenocarcinoma [PDAC]).
METHODS
METHODS
National Cancer Data Base (NCDB)-pancreatectomy patients who underwent NCT/NRT were included. The NCT-S interval was divided into time quintiles in weeks: 8 to 11, 12 to 14, 15 to 19, 20 to 29, and >29 weeks.
RESULTS
RESULTS
A total of 2093 patients with NCT were included with median follow-up of 74 months and 71% NRT. The pCR rate was 2.1% with higher median OS compared with non-pCR (41 vs 19 months,
CONCLUSIONS
CONCLUSIONS
Longer NCT-S interval and pCR were independent predictors of improved OS in patients with PDAC. The NRT predicted increased pCR but not OS.
Identifiants
pubmed: 32669884
doi: 10.1177/1179554920919402
pii: 10.1177_1179554920919402
pmc: PMC7336830
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1179554920919402Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Semin Oncol. 2015 Feb;42(1):144-62
pubmed: 25726059
Ann Surg Oncol. 2008 Oct;15(10):2661-7
pubmed: 18389322
Arch Surg. 1992 Nov;127(11):1335-9
pubmed: 1359851
Cancer Med. 2017 Jun;6(6):1201-1219
pubmed: 28544758
Cancer. 2013 Aug 1;119(15):2692-700
pubmed: 23720019
Ann Surg. 2018 Jul;268(1):1-8
pubmed: 29334562
Ann Surg Oncol. 2008 Mar;15(3):683-90
pubmed: 18183467
J Radiat Oncol. 2013 Dec;2(4):413-425
pubmed: 25755849
Ann Surg Oncol. 2013 Nov;20(12):3787-93
pubmed: 23904005
Ann Surg Oncol. 2009 Jul;16(7):1727-33
pubmed: 19396496
JAMA Surg. 2016 Nov 16;151(11):e162743
pubmed: 27627765
Ann Surg Oncol. 2014 Feb;21(2):662-9
pubmed: 24276638
J Surg Oncol. 1989 Mar;40(3):143-51
pubmed: 2918720
Ann Diagn Pathol. 2012 Jan;16(1):29-37
pubmed: 22050964
Dis Colon Rectum. 2004 Mar;47(3):279-86
pubmed: 14991488
Dis Colon Rectum. 2003 Mar;46(3):298-304
pubmed: 12626903
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
J Clin Oncol. 2006 Aug 20;24(24):3953-8
pubmed: 16921048
Ann Surg. 2009 Oct;250(4):582-9
pubmed: 19710605
Am J Surg. 2008 Mar;195(3):318-21
pubmed: 18308038
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Br J Cancer. 2008 Jul 8;99(1):6-13
pubmed: 18577990
J Am Coll Surg. 2015 Aug;221(2):430-40
pubmed: 26206642
Ann Surg Oncol. 2011 Dec;18(13):3601-7
pubmed: 21947697
Ann Surg Oncol. 2006 Feb;13(2):150-8
pubmed: 16418882
Cancer. 2012 Jan 1;118(1):268-77
pubmed: 21735446
Cancer. 2012 Dec 1;118(23):5749-56
pubmed: 22605518
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Eur J Surg Oncol. 2010 Oct;36(10):987-92
pubmed: 20828979
Cancer. 2012 Jun 15;118(12):3182-90
pubmed: 22028089
Ann Surg Oncol. 2010 Apr;17(4):1159-67
pubmed: 20140529
JAMA Surg. 2017 Nov 1;152(11):1048-1056
pubmed: 28700784
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
HPB (Oxford). 2010 Feb;12(1):73-9
pubmed: 20495649
Ann Surg Oncol. 2010 Nov;17(11):2832-8
pubmed: 20725860
Medicine (Baltimore). 2015 Dec;94(52):e2168
pubmed: 26717359
J Surg Oncol. 2011 Aug 1;104(2):155-61
pubmed: 21520097
Ann Thorac Surg. 2015 Jan;99(1):270-6
pubmed: 25440267
Am J Surg Pathol. 2016 Dec;40(12):1653-1660
pubmed: 27631521
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Ann Surg Oncol. 2014 May;21(5):1530-7
pubmed: 24473642
Radiother Oncol. 2015 Jan;114(1):122-7
pubmed: 25614389
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005